Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease

Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease

Background: Patients with relapsing–remitting multiple sclerosis (RRMS) may experience breakthrough disease despite effective interferon beta (IFNβ) therapy. Fludarabine (FLU) is a chemotherapeutic agent used in lymphoproliferative disorders that may be synergistic when combined with immunomodulator...

Full description

Bibliographic Details
Main Authors: Steven J. Greenberg, Robert Zivadinov, Peterkin Lee-Kwen, Jitendra Sharma, Margaret Planter, Margaret Umhauer, Norman Glenister, Rohit Bakshi
Format: Article
Language:English
Published: SAGE Publishing 2016-03-01
Series:Therapeutic Advances in Neurological Disorders
Online Access:https://doi.org/10.1177/1756285615626049

Internet

https://doi.org/10.1177/1756285615626049

Similar Items